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Summary 
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase 
II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four 
patients with a bilirubin _< 1.5 mg% received mitoxantrone 12 mg/m 2 i.v. repeated every three weeks. 
Myelosuppression in the form of  leukopenia was the major toxicity. There were no responses in twenty-four 
evaluable patients. 
Introduction Materials and methods 
Mitoxantrone (Novantrone; dihydroxyanthracene- 
dione) is one of  the anthracenedione derivatives 
synthesized in an attempt to find an agent with the 
same or better antitumor activity than adriamycin 
without its dose-limiting cardiotoxicity [1,2]. Phase 
I studies showed mitoxantrone to be well tolerated 
with reversible myelosuppression as its dose-limit- 
ing toxicity [3]. Its anti tumor activity has been simi- 
lar to adriamycin. 
In order to insure an appropriate distribution of 
untreated patients on Phase II trials in advanced 
pancreatic cancer, the Southwest Oncology Group 
initiated a series of  randomized Phase II trials. We 
report a trial of  mitoxantrone in advanced adeno- 
carcinoma of  the pancreas. 
Previously untreated patients were randomized to a 
combination of fluorouracil, adriamycin, mitomy- 
cin and streptozotocin (FAM-S) or to mitoxantrone 
as a single agent. At relapse or disease progression 
patients who still met eligibility requirements were 
reregistered and crossed over to the other arm. 
Patient eligibility included histologic confirma- 
tion of adenocarcinoma of  the pancreas not amena- 
ble to curative surgery or radiation; objective mea- 
surable disease; a life expectancy of at least six 
weeks; a performance status of  three or better by 
SWOG criteria; WBC count _> 3500/mm3; a plate- 
let count of ~ 125,000 mm 3, a serum creatinine _< 
2.0 mg%. There were no age restrictions. Patients 
had received no chemotherapy except at cross-over. 
At cross-over patients had recovered from any 
acute toxicities and had received no chemotherapy 
for six weeks. Patients with past or present history 
of congestive heart failure were not eligible. In pa- 
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tients with recent abdominal surgery, treatment was 
held for 3 weeks or until recovery of bowel func- 
tion, whichever occurred later. Concomitant  ra- 
diation therapy was allowed for painful boney 
metastases only. Patients were stratified by perfor- 
mance status (0-1  vs 2 - 3 )  and according to 
whether biopsy only or palliative bypass procedures 
were performed. 
During treatment,  weekly complete blood counts, 
WBC and differentials, and platelets were moni- 
tored. Tumor  measurements, kidney and liver func- 
tion tests, EKG's ,  and performance status were ob- 
tained prior to each course. 
Cardiac ejection fractions determined by gated 
radionuclide angiography were obtained in all pa- 
tients pretreatment and monitored thereafter in 
those patients who had received their maximal dose 
of adriamycin or who had received mitoxantrone 
for six weeks or more. 
Doses of  mitoxantrone were adjusted for hepatic 
function. The initial dose of  mitoxantrone for pa- 
tients with a bilirubin _< 1.5 rag% (good risk) was 
12 m g / m  2 given as a 30 minute infusion in 100 c c  
of  DsW through a freely running intravenous line. 
Patients with an abnormal bilirubin were consi- 
dered as poor risk and treated with reduced doses. 
Patients with a bilirubin between 1 .5-3 .0  rag% 
received 6 m g / m  2 and patients with a bilirubin of 
greater than 3 rag% received 4.5 m g / m  2. The treat- 
ment was repeated every three weeks provided the 
patient had recovered from previous drug induced 
toxicity. Doses for subsequent courses were adjust- 
ed based upon previous drug induced toxicity. Pa- 
tients without side-effects (WBC _> 4000/mm 3, 
Platelets ~ 100,000/mm 3) had their doses in- 
creased by 10%. Patients with WBC 2000-3900/  
mm 3 or platelets 50 ,000-90,000/mm 3 which had 
resolved at 3 weeks received the same dose. Patients 
with WBC 1000-1900/mm 3 or platelets 25,000- 
49,900/mm 3 or requiring more than 1 week to 
recover had their dose reduced by 17%. Patients 
with life threatening toxicity (WBC < 1000/ram 3, 
platelets < 25,000/m 3) had their dose reduced by 
50%. 
Response and survival duration were calculated 
f rom the initial date of  treatment. Complete remis- 
sion was defined as complete disappearance of all 
Table 1. Patient characteristics of  previously untreated patients 
Good risk Poor risk 
No. entered 24 5 
Evaluable 24 5 
P.S.: Median 2 2 
P.S.: Range 0 - 3  0 - 3  
Age: Median 54 66 
Age: Range 27-82  34-70  
Biopsy only 19 3 
Diversion procedure 5 2 
Courses: 
Administered 62 6 
Median 2 1 
Range 1 - 10 1 - 2 
Response: 
Progression 19 4 
Early death 2 1 
Stable 3 0 
Survival (months): 
Median 3.1 1.4 
clinical evidence of tumor  for a minimum of four 
weeks. Partial remission was defined as 50% or 
greater decrease in the sum of the products of  all 
diameters of  measured lesions with no new disease 
or increase in size of  any lesion. Progression was de- 
fined as the unequivocal increase of  at least 25% in 
the size of  any measurable lesion or the appearance 
of new lesions. 
Results 
Thirty-six patients were registered on study. All pa- 
tients were eligible and all were evaluated. Patient 
characteristics are presented in Table 1. 
Twenty-four previously untreated good risk pa- 
tients were evaluable and received mitoxantrone at 
12 m g / m  2. Three patients had stable disease for 73, 
195 and 233 days. Twenty-one patients had pro- 
gressive disease with two early disease related 
deaths (days 3 and 8). 
Five untreated poor risk patients received re- 
duced doses of  mitoxantrone (3 at 4.5 m g / m  2 level 
and 2 at 6.0 m g / m  2 level). There were no objective 
responses. There was one early death due to disease 
at day 14. The survival curves for these two groups 
of patients (good and poor risk previously untreat- 












DHAD Good Risk 
OHAD Poor Risk 
12 18 
WOHTHS AFTZR REGISTRATION 





Fig. 1. Overall survival eligible patients with follow-up. 
Seven patients were randomized to mitoxantrone 
after failing FAM-S. Three good risk patients 
received eight courses at 12 mg/m 2. One patient 
treated with 6 mg/m 2 was lost to follow up and the 
second patient died day seven due to disease. One 
patient was treated with 4.5 mg/m 2 and expired 
after one course. One patient was treated with only 
3 mg/m 2 due to dose reduction error. She expired 
on day three. There were no objective responses. 
Toxic i ty  
Myelosuppression in the form of leukopenia was 
the major toxicity in the good risk group. Forty-two 
courses at the 12 mg/m 2 dose were evaluable for 
myelosuppression. The median leukocyte nadir for 
this group was 2300/mm 3 (Range 500-  > 20,000). 
The median platelet nadir was > 150,000/mm 3. 
One patient with concomitant sepsis had a platelet 
count of  24,000/mm 3. Drops in hemoglobin (1 -3  
grams) without documented bleeding were seen in 
5 patients. Two patients required dose reductions 
of  10% in seven courses. Dose escalation by 10% 
was required in two patients. Leukocyte counts of 
2,999 (1000 granulocytes) or less were observed in 
72% of  the courses. Mild nausea, vomiting and 
alopecia were observed. There were no treatment 
related deaths. 
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Myelosuppression was minimal in the poor risk 
patients treated. Two courses of  six were not evalu- 
able for hematologic toxicity due to early death. 
The median leukocyte nadir was > 4000/mm 3. The 
platelet nadir was _> 100,000/mm 3. One patient 
had an unexplained 2 gram drop in hemoglobin. 
Two patients had mild nausea and vomiting. 
In the cross-over group receiving mitoxantrone 
as second line therapy, toxicity was poorly 
documented. Ten courses were not evaluable for 
hematologic toxicity (one patient was lost to follow 
up, and there were three early deaths). In the two 
courses for which hematologic data was available, 
there was no myelosuppression. 
Cardiac toxicity was difficult to assess due to the 
limited number of patients who received significant 
cumulative doses. Five good risk patients received 
four or more courses of mitoxantrone with no 
change in ejection fractions by gated radionuclide 
angiography. One patient experienced an episode 
of paroxysmal atrial tachycardia between courses 
three and four. This was not temporally related to 
her treatment and did not require hospitalization. 
There was no other clinical or EKG evidence of 
cardiotoxicity. 
Conclusion 
Mitoxantrone was well tolerated, but showed no 
objective responses in this group of patients, which 
included twenty-four previously untreated in- 
dividuals who received adequate doses of drug. The 
95~ confidence level for this group of patients is 
0-14.3~ We conclude that mitoxantrone, ad- 
ministered at 12 mg/m 2 every 3 weeks has no ac- 
tivity in advanced adenocarcinoma of  the pancreas. 
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